TrialPath

Find a study

Match me to a study

46 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

40 studies on the map

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis — Sun Valley Arthritis Center /ID# 278331, PeoriaA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamRA-PRO PRAGMATIC TRIAL — East Alabama Arthritis Center PC, AuburnBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. — Artiva Investigational Site Tuscaloosa, TuscaloosaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis — Research Site, GlendaleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — SunValley Arthritis Center Ltd., PeoriaA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaA Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) — Arizona Arthritis & Rheumatology Associates, GilbertA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) — Nkarta Investigational Site, OrangeA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadHyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis — Byers Hall, San FranciscoA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonA Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis — Nouvelle Clinical Research LLC, Cutler BaySafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityDynamic Treatment Regiments for Glucocorticoid Tapering — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT — UPMC Children's Hospital of Pittsburgh, PittsburghPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response — University of Nebraska Medical Center, OmahaAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis — DM Clinical Research, TomballMechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype — University of Michigan, Ann ArborTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) — National Institutes of Health Clinical Center, BethesdaMolecular Imaging of NET Using [C-11]MRB-PET in MS — Brigham MS Center, 60 Fenwood Road, BostonEffect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques — National Institutes of Health Clinical Center, BethesdaSolriamfetol for the Treatment of Multiple Sclerosis Fatigue — Johns Hopkins University, BaltimoreComparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection — University of Kansas Medical Center- Sleep, Health and Wellness Laboratory, Kansas CityNasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis — Brigham and Women's Hospital, BostonAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoEfficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis — University of Kansas Medical Center, Kansas CityMetformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) — UBMD Neurolgy, Buffalo